Laxative free bowel prep visualized on Viatronix V3D-Colon platform

Viatronix Incorporated, a leading innovator and developer of 2D/3D medical imaging and diagnostic software today announced that their V3D®-Colon platform was exclusively used to perform a key study recently published in the Annals of Internal Medicine. The purpose of the study was to determine the feasibility of a laxative free bowel prep for patients undergoing a virtual colonoscopy (VC), screening exam. The trial utilized a modified version of the Viatronix V3D®-Colon software.

"The trial performed by the research group led by Dr. Michael Zalis at Massachusetts General Hospital demonstrates an option for a laxative free bowel prep and was visualized on the Viatronix V3D®-Colon platform," said Zaffar Hayat, CEO & President of Viatronix Incorporated. "CT Colonography (CTC), also known as virtual colonoscopy has been clinically proven over the past decade in multiple trials and is being adopted worldwide as a reliable alternative for colorectal cancer screening. Viatronix has been at the forefront of CTC research for many years and welcomes the scientific progress resulting from this study."

VC is now being reimbursed by insurance carriers in approximately 30 states within the U. S. Both the US House and Senate have introduced legislation that will require coverage of VC as a colon cancer screening benefit under Medicare. Adding CTC to the list of approved screening services will increase compliance with screening guidelines and has the potential to reduce unnecessary deaths from this cancer.

Every year over 50,000 Americans die from colorectal cancer in the U.S. and another 150,000 new cases of colorectal cancer are diagnosed. Colorectal Cancer is more than 90% preventable through early screening. Viatronix has been a leader in the field of virtual colonoscopy for over a decade and has supported research with a goal to provide the patients with a less invasive screening alternative.